Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;27(12):2520-7.
doi: 10.1007/s11095-010-0255-y. Epub 2010 Sep 8.

Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles

Affiliations

Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles

Ebbe J B Nielsen et al. Pharm Res. 2010 Dec.

Abstract

Purpose: This work describes the production and application of an aerosolised formulation of chitosan nanoparticles for improved pulmonary siRNA delivery and gene silencing in mice.

Methods: Aerosolised chitosan/siRNA nanoparticles were pneumatically formed using a nebulising catheter and sized by laser diffraction. In vitro silencing of aerosolised and non-aerosolised formulations was evaluated in an EGFP endogenous-expressing H1299 cell line by flow cytometry. Non-invasive intratracheal insertion of the catheter was used to study nanoparticle deposition by histological detection of Cy3-labeled siRNA and gene silencing in transgenic EGFP mouse lungs using a flow cytometric method.

Results: Flow cytometric analysis demonstrated minimal alteration in gene silencing efficiency before (68%) and after (62%) aerosolisation in EGFP-expressing H1299 cells. Intratracheal catheter administration in mice resulted in nanoparticle deposition throughout the entire lung in both alveoli and bronchiolar regions using low amounts of siRNA. Transgenic EGFP mice dosed with the aerosolised nanoparticle formulation showed significant EGFP gene silencing (68% reduction compared to mismatch group).

Conclusions: This work provides a technology platform for effective pulmonary delivery and gene silencing of RNAi therapeutics with potential use in preclinical studies of respiratory disease treatment.

PubMed Disclaimer

References

    1. J Leukoc Biol. 2005 Jun;77(6):846-53 - PubMed
    1. Pharm Res. 1994 Sep;11(9):1358-61 - PubMed
    1. J Morphol. 1996 Dec;230(3):291-7 - PubMed
    1. Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5679-84 - PubMed
    1. Nat Rev Drug Discov. 2007 Jun;6(6):443-53 - PubMed

Publication types

LinkOut - more resources